Oral oncology最新文献

{"title":"Letter to Editor on, “Impact of radiation dose to the swallowing organs on death from aspiration pneumonia in oral cavity cancer.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107319","DOIUrl":"10.1016/j.oraloncology.2025.107319","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107319"},"PeriodicalIF":4.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143838472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma","authors":"A.R. Koskenniemi ,&nbsp;T. Huusko ,&nbsp;J. Routila ,&nbsp;S. Jalkanen ,&nbsp;M. Hollmén ,&nbsp;P. Vainio ,&nbsp;S. Ventelä","doi":"10.1016/j.oraloncology.2025.107287","DOIUrl":"10.1016/j.oraloncology.2025.107287","url":null,"abstract":"<div><h3>Objective</h3><div>Despite growing interest in neoadjuvant therapies, there are no methods to predict radio- (RT) or chemoradiotherapy (CRT) response in head and neck squamous cell carcinoma (HNSCC). The aim of this research was to study the effect of neoadjuvant RT or CRT on the tumor immune landscape and patient survival in HNSCC.</div></div><div><h3>Methods</h3><div>All HNSCC patients treated with neoadjuvant RT or CRT (n = 53) were identified from a retrospective cohort of 1033 patients. Pre- and post-neoadjuvant cancer samples from the same patient were analyzed with biomarkers related to cancer immunology: tumor-infiltrating lymphocytes (CD8), tumor-associated macrophages (CD68, CD206, Clever-1), immune response regulator (PD-L1) and histologic tumor necrosis. Outcomes of interest were individual immune landscape profiling and its impact on 5-year overall survival (OS) in HNSCC patients treated with neoadjuvant RT/CRT.</div></div><div><h3>Results</h3><div>Results from 588 whole-section stainings revealed multiple statistically significant alterations in immune landscape in response to RT/CRT. Pretreatment tumor necrosis was the most useful biomarker in predicting poor outcome, as the OS was 14.3% with necrosis and 48.5% without necrosis (HR 2.87; 95% CI: 1.23 to 6.66, p=0.014). In addition, an artificial intelligence-based (AI) deep learning method for identifying tumor necrosis from histopathological specimens was successfully developed. The predictive role of histological necrosis in neoadjuvant RT/CRT was validated in additional samples from 171 HNSCC patients untreated with neoadjuvant therapy.</div></div><div><h3>Conclusions</h3><div>Detection of tumor necrosis and AI-driven deep learning effectively predict neoadjuvant RT/CRT responses in HNSCC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107287"},"PeriodicalIF":4.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on, “Refining prognostic subcategories in intermediate-advanced glottic cancer: A multicentric study on 637 patients treated by transoral laser microsurgery”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107300","DOIUrl":"10.1016/j.oraloncology.2025.107300","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107300"},"PeriodicalIF":4.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on, “Effect of Enhanced Recovery After Radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107302","DOIUrl":"10.1016/j.oraloncology.2025.107302","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107302"},"PeriodicalIF":4.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to Editor on, “Neoadjuvant chemoradiation for patients with resectable locally advanced oral cavity squamous cell carcinoma: Results of the prospective INVERT clinical trial.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107301","DOIUrl":"10.1016/j.oraloncology.2025.107301","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107301"},"PeriodicalIF":4.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular features of T and N stage progression in laryngeal cancer","authors":"Nicholas Li ,&nbsp;Peter Y.F. Zeng ,&nbsp;Hugh A.J Kim ,&nbsp;Amir Karimi ,&nbsp;Shengjie Ying ,&nbsp;Mushfiq H. Shaikh ,&nbsp;Halema Khan ,&nbsp;Krista Joris ,&nbsp;MohdWessam Al Jawhri ,&nbsp;Matthew Cecchini ,&nbsp;Joe S. Mymryk ,&nbsp;John W. Barrett ,&nbsp;Anthony C. Nichols","doi":"10.1016/j.oraloncology.2025.107283","DOIUrl":"10.1016/j.oraloncology.2025.107283","url":null,"abstract":"<div><div>Laryngeal squamous cell cancer (LSCC) is a common type of head and neck cancer that is typically unrelated to human papilloma virus (HPV) infection. Late-stage laryngeal cancers are associated with greater morbidity due to obstructive symptoms, and poorer overall survival. Using data from The Cancer Genome Atlas (TCGA), we analyzed 112 patient LSCC samples, comparing patient proteome, transcriptome and genome between early and late T and N samples. We observed significant differences in SNV frequency for various genes between the early and late-stage groups. Most notably we observed that NOTCH1 mutation, which was more frequent in late N-stage supraglottic cancers, was also associated with poorer patient survival in LSCCs. Methylation analysis also revealed changes in JUN gene methylation in late N glottic cancers. Transcriptomic analysis revealed differential expression in c-JUN, HOXB7 and HOXB9 transcript levels, suggesting potential involvement of these pathways in progression and nodal involvement. Our findings illustrate that LSCC undergoes distinct molecular changes associated with different stages and subsites. We observed multiple potential markers for progression, metastases and survival, including NOTCH1 mutation, which may aid as prognostic indicators in future studies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107283"},"PeriodicalIF":4.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation","authors":"Anouk V.M. Burger ,&nbsp;Melissa A. Koot ,&nbsp;Dorieke E.M. van Balen ,&nbsp;Anouk W.M.A. Schaeffers ,&nbsp;Charlotte L. Zuur ,&nbsp;Lot A. Devriese ,&nbsp;Micha de Ridder ,&nbsp;Alex E. Hoetink ,&nbsp;Tim Schutte ,&nbsp;Mirjam Crul","doi":"10.1016/j.oraloncology.2025.107246","DOIUrl":"10.1016/j.oraloncology.2025.107246","url":null,"abstract":"<div><h3>Introduction</h3><div>Head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin-based chemoradiation often suffer from cisplatin-induced hearing loss (CIHL). To prevent toxicities, patients receive hydration before and after cisplatin infusions. This study evaluated cisplatin-induced hearing loss between a long and short duration of infusion and volume of hydration schedule (DIVHS).</div></div><div><h3>Methods</h3><div>Between 2019 and 2023, 161 patients were included in two Dutch hospitals. Patients received either weekly cisplatin (Cis40qw, n = 77) or triweekly cisplatin (Cis1003q3w, n = 88). Two different short and long DIVHS were used in each cisplatin regimen. Pure tone audiometry was performed at baseline and three months after chemoradiation. Pure tone averages (PTA) were calculated for PTA 1–2–4 kHz and PTA 8–10–12.5 kHz. CIHL was assessed using mean threshold shift.</div></div><div><h3>Results</h3><div>In the Cis40qw group, the mean threshold shift at PTA 1–2–4 kHz was 3.1 dB in the short and 4.7 dB in the long DIVHS (<em>p</em> = 0.37). In the Cis100q3w cohort, the mean threshold shift was 5.3 dB in the short and 7.1 dB in the long DIVHS (<em>p</em> = 0.36). At PTA 8–10–12.5 kHz, the mean threshold shifts of the Cis40qw groups were 11.8 dB in the short versus 15.4 dB in the long DIVHS (<em>p</em> = 0.30). In the Cis100q3w cohort, the mean threshold shift was 19.9 dB in the short compared to 19.4 dB in the long DIVHS (<em>p</em> = 0.85).</div></div><div><h3>Conclusion</h3><div>This study found no significant difference in CIHL between different DIVHS during cisplatin-based chemoradiation in HNSCC patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107246"},"PeriodicalIF":4.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The patterns of systemic metastasis in major salivary gland cancer and therapeutic implications","authors":"Subi Oh ,&nbsp;Younghac Kim ,&nbsp;Hyojun Kim ,&nbsp;Eunhye Kim ,&nbsp;Sook-young Woo ,&nbsp;Nayeon Choi ,&nbsp;Junhun Cho ,&nbsp;Dongryul Oh ,&nbsp;Yong-Chan Ahn ,&nbsp;Sehhoon Park ,&nbsp;Myung-Ju Ahn ,&nbsp;Han-Sin Jeong","doi":"10.1016/j.oraloncology.2025.107258","DOIUrl":"10.1016/j.oraloncology.2025.107258","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to investigate the patterns of metastatic spread of salivary gland cancer (SGC) and their therapeutic implications. Patterns of systemic metastasis, post-metastasis survival, and risk factors have not been defined clearly in SGC, and the validity of the concept of oligometastasis in SGC has never been explored.</div></div><div><h3>Methods</h3><div>This was a retrospective study of SGC patients with systemic metastasis (N = 199). The primary outcome was post-metastasis disease-specific survival, and multivariable survival analyses for risk factors were performed. The patients were divided into three pathology groups, adenoid cystic carcinomas (ACCs), non-ACC high-grade tumors, and non-ACC intermediate or low-grade tumors.</div></div><div><h3>Results</h3><div>Median survival was 28.9 months after diagnosis of systemic metastasis. Only 30 % of patients had oligometastasis (≤ 3 metastatic lesions and ≤ 2 involved organs), and polymetastasis was observed in 70 % (33.7 % single organ polymetastasis and 36.2 % multi-organ polymetastasis). Poor patient performance status, shorter metastasis-free interval, non-ACC high-grade tumor, concurrent local disease, and multi-organ polymetastasis were identified as independent risk factors for post-distant metastasis survival. Of note, SGC patients with oligometastasis and single organ polymetastasis showed similar survival outcomes. Systemic chemotherapy did not improve post-metastasis survival of SGC patients significantly. However, HER-2 targeted therapy combined with chemotherapy extended post-metastasis survival in c-erb-B2 expressing tumors.</div></div><div><h3>Conclusions</h3><div>Systemic metastasis into multiple organs is a common pattern of SGC metastasis, and significantly affects patient survival. Tumor biology-based therapy should be further sought for improving post-metastasis outcomes of SGC patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107258"},"PeriodicalIF":4.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer","authors":"Luigi Lorini ,&nbsp;Riccardo Gili ,&nbsp;Carlo Resteghini ,&nbsp;Riccardo Gerosa ,&nbsp;Luigi Cecchi ,&nbsp;Cristina Gurizzan ,&nbsp;Alberto Zambelli ,&nbsp;Paolo Andrea Zucali ,&nbsp;Paolo Bossi","doi":"10.1016/j.oraloncology.2025.107296","DOIUrl":"10.1016/j.oraloncology.2025.107296","url":null,"abstract":"<div><div>Salivary Gland Carcinomas (SGC) are a heterogeneous group of diseases with varied histologies, biology, clinical behaviors, and therapeutic approaches. The World Health Organization classifies SGCs into Low Aggression and High Aggression categories. Due to their rarity and unique biology, managing SGCs is challenging, often requiring expert histological diagnosis and treatment based on low-level evidence. Despite recent international guidelines, several critical aspects of SGC management remain unresolved, in particular regarding systemic treatment. Recent discoveries of molecular alterations, such as HER2 amplification, and AR overexpression, have provided diagnostic, prognostic, and predictive biomarkers for alternative treatments. While some targeted treatment have corresponding EMA-approved therapies, others do not. Treatment strategies are further complicated by synchronous alterations, such as AR-positive SGCs with concomitant HER2 amplification. Open questions remain on the optimal use of these drugs, whether in early-stage disease, post-surgery, or in palliative settings. Given the rarity of the disease and the consequent lack of high quality data in literature, it is of importance a cross-fertilization process from other, more common disease such as breast and prostate cancers. In the current narrative review we analyze current evidence on the targeted treatment on salivary gland carcinomas and shared features with breast and prostate cancer.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107296"},"PeriodicalIF":4.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on “Histopathological invasion patterns and prognosis in oral squamous cell carcinoma: A retrospective analysis of 560 Cases”","authors":"Jospin Sindya,&nbsp;Jeevitha Rajanathadurai,&nbsp;Elumalai Perumal","doi":"10.1016/j.oraloncology.2025.107297","DOIUrl":"10.1016/j.oraloncology.2025.107297","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107297"},"PeriodicalIF":4.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143815937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}